A 
argenx ARGX.BR · EUR
Health Care · Biotechnology · Euronext Brussels · 🇧🇪 Belgium
Euro Stoxx 50
853.80
+4.66%
Close of 9 Nov 2026, in EUR
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
At a glance
Figures in USD, from our data supplier.
Revenue
$3.60bn
FY2016FY2025
Net income
$1.12bn
FY2016FY2025
Free cash flow
$731.6m
FY2016FY2025
Shareholders' equity
$6.35bn
FY2016FY2025
Income statement
Fiscal years
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.60bn | $1.90bn | $1.23bn | $410.7m | $1.08bn | $41.2m | $78.5m | $24.6m | $43.7m | $15.5m |
| Research and development | $1.18bn | $852.1m | $859.5m | $663.4m | $580.5m | $370.5m | $220.8m | $95.6m | $62.1m | $33.2m |
| Operating income | $913.8m | −$18.8m | −$425.0m | −$720.3m | −$398.6m | −$603.9m | −$198.9m | −$93.6m | −$27.5m | −$22.5m |
| Net income | $1.12bn | $721.8m | −$295.1m | −$709.6m | −$408.3m | −$608.5m | −$181.2m | −$76.2m | −$33.7m | −$22.5m |
| Diluted earnings per share | 16.91 | 10.17 | -5.03 | -12.83 | -7.93 | -12.85 | -4.59 | -2.21 | -1.23 | -1.11 |
Balance sheet
At each fiscal year end
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $7.52bn | $5.37bn | $4.54bn | $3.13bn | $2.85bn | $2.28bn | $1.61bn | $661.7m | $445.0m | $111.2m |
| Cash and short-term investments | $3.85bn | $2.93bn | $3.18bn | $2.19bn | $2.34bn | $2.00bn | $1.50bn | $645.8m | $431.6m | $101.7m |
| Total liabilities | $1.18bn | $610.2m | $445.0m | $320.6m | $316.1m | $605.4m | $429.8m | $45.8m | $31.2m | $44.6m |
| Debt | $9.4m | $39.1m | $20.0m | $12.4m | $11.5m | $9.7m | $7.3m | — | — | — |
| Shareholders' equity | $6.35bn | $4.76bn | $4.10bn | $2.81bn | $2.53bn | $1.67bn | $1.18bn | $615.9m | $413.8m | $66.7m |
| Shares outstanding | 66m | 71m | 59m | 55m | 52m | 47m | 39m | 34m | 27m | 20m |
Cash flow
Fiscal years
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | $736.9m | −$71.7m | −$420.3m | −$862.8m | −$606.8m | −$398.5m | $151.6m | −$61.6m | −$43.8m | $11.1m |
| Capital spending | −$5.4m | −$59.2m | −$43.8m | −$103.8m | −$121.4m | −$5.1m | −$46.7m | −$782,000 | −$421,000 | −$906,000 |
| Free cash flow | $731.6m | −$130.9m | −$464.1m | −$966.6m | −$728.2m | −$403.6m | $104.9m | −$62.4m | −$44.3m | $10.2m |
| Dividends paid | — | — | — | −$5.5m | — | — | — | — | — | — |
Financial ratios
Data as of 19 Sept 2026
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | |
|---|---|---|---|---|---|---|
| Operating margin | 24.8% | -1.0% | -34.7% | -175.4% | -75.5% | -1672.1% |
| Net margin | 32.4% | 37.1% | -24.1% | -172.8% | -77.3% | -1681.8% |
| Return on equity | 18.4% | 15.2% | -7.2% | -25.2% | -16.1% | -36.3% |
| Return on assets | 15.5% | 13.4% | -6.5% | -22.6% | -14.3% | -26.7% |
| Free cash flow yield | 1.5% | -0.1% | -0.7% | -1.6% | -1.1% | -1.0% |
| Revenue growth | 84.7% | 83.3% | 198.6% | -22.2% | 1360.2% | -53.9% |
| Earnings growth | 61.4% | -382.3% | -58.4% | 73.8% | -32.9% | 235.8% |
| Current ratio | 5.23x | 7.29x | 9.75x | 9.18x | 8.44x | 6.26x |
| Debt to equity | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x |
| Equity ratio | 84.3% | 88.6% | 90.2% | 89.8% | 88.9% | 73.4% |
| Interest coverage | 242.70x | -8.79x | -470.19x | -328.47x | -363.73x | -1719.77x |
| R&D as a share of sales | 34.2% | 42.2% | 70.1% | 161.5% | 109.9% | 1025.1% |
| Buybacks as a share of market value | 6.7% | -21.0% | -6.0% | -7.4% | -8.8% | -19.9% |
Growth per year
Compound annual rate
| 3 years | 5 years | 10 years | |
|---|---|---|---|
| Revenue | 106.2% | 144.4% | 85.4% |
Average margins
Over each period
| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Operating margin | 16.3% | -3.5% | -15.2% | -19.1% |
| Net margin | 33.5% | 11.7% | -2.2% | -6.1% |
Valuation history
At each fiscal year end
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Price to earnings | 49.0 | 68.2 | -79.0 | -31.4 | -46.0 | -21.8 | -36.2 | -44.5 | -49.5 | -16.6 |
| Price to sales | 15.3 | 25.9 | 19.0 | 54.2 | 17.4 | 321.3 | 83.5 | 138.2 | 38.2 | 24.2 |
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.